blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2785184

EP2785184 - COMPOSITIONS COMPRISING JAK INHIBITORS AND HAART DRUGS FOR USE IN THE PREVENTION OR TREATMENT OF HIV [Right-click to bookmark this link]
Former [2014/41]ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS
[2019/51]
StatusNo opposition filed within time limit
Status updated on  16.04.2021
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  08.05.2020
FormerGrant of patent is intended
Status updated on  15.01.2020
FormerExamination is in progress
Status updated on  17.03.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Emory University
Office of Technology Transfer 1599 Clifton Road 4th Floor
Atlanta, GA 30322 / US
[2020/24]
Former [2014/41]For all designated states
Emory University
Office of Technology Transfer 1599 Clifton Road 4th Floor
Atlanta, GA 30322 / US
Inventor(s)01 / GAVEGNANO, Christina
477 Sherman Way
Decatur, GA 30033 / US
02 / SCHINAZI, Raymond, F.
1100 Biscayne Blvd.
Apt 2101
Miami, Florida 33132 / US
 [2020/24]
Former [2014/41]01 / GAVEGNANO, Christina
477 Sherman Way
Decatur, GA 30033 / US
02 / SCHINAZI, Raymond, F.
1100 Biscyne Blvd.
Apt 2101
Miami, Florida 33132 / US
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2014/41]HGF Limited
Delta House
50 West Nile Street
Glasgow G1 2NP / GB
Application number, filing date12852554.030.11.2012
[2020/24]
WO2012US67369
Priority number, dateUS201161564994P30.11.2011         Original published format: US 201161564994 P
US201161570813P14.12.2011         Original published format: US 201161570813 P
[2014/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013082476
Date:06.06.2013
Language:EN
[2013/23]
Type: A1 Application with search report 
No.:EP2785184
Date:08.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 06.06.2013 takes the place of the publication of the European patent application.
[2014/41]
Type: B1 Patent specification 
No.:EP2785184
Date:10.06.2020
Language:EN
[2020/24]
Search report(s)International search report - published on:US06.06.2013
(Supplementary) European search report - dispatched on:EP06.07.2015
ClassificationIPC:A61K31/52, A61K31/4045, A61K31/513, A61K31/519, A61K31/536, A61K31/7072, A61K31/66, A61P31/18
[2019/51]
CPC:
A61K31/519 (EP,CN,US); A61K31/4045 (EP,US); A61K31/513 (EP,US);
A61K31/52 (EP,CN,US); A61K31/536 (EP,CN,US); A61K31/66 (EP,CN,US);
A61K31/7072 (EP,CN,US); A61K45/06 (CN,US); A61P31/18 (EP);
A61P31/20 (EP); A61P31/22 (EP); A61P43/00 (EP);
Y02A50/30 (EP,US) (-)
Former IPC [2015/16]A61K31/52, A61P31/12, A61P31/18, A61P31/20, A61P31/22, A61P43/00
Former IPC [2014/41]A01N43/90
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/41]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNGEN ENTHAlTEND JAK-HEMMER UND HAART-MEDIKAMENTE ZUR VORBEUGUNG ODER BEHANDLUNG VON HIV[2019/52]
English:COMPOSITIONS COMPRISING JAK INHIBITORS AND HAART DRUGS FOR USE IN THE PREVENTION OR TREATMENT OF HIV[2019/51]
French:COMPOSITIONS CONTENANT DES INHIBITEURS DE JAK ET DES MÉDICAMENTS HAART DESTINÉES À LA PRÉVENTION OU AU TRAITEMENT DU VIH[2019/51]
Former [2014/41]ANTIVIRALE JAK-INHIBITOREN ZUR BEHANDLUNG ODER VORBEUGUNG VON RETROVIRALEN UND ANDEREN VIRALEN INFEKTIONEN
Former [2014/41]ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS
Former [2014/41]INHIBITEURS DE JAK ANTIVIRAUX UTILES DANS LE TRAITEMENT OU LA PRÉVENTION D'INFECTIONS RÉTROVIRALES ET AUTRES INFECTIONS VIRALES
Entry into regional phase12.05.2014National basic fee paid 
12.05.2014Search fee paid 
12.05.2014Designation fee(s) paid 
12.05.2014Examination fee paid 
Examination procedure12.05.2014Examination requested  [2014/41]
02.02.2016Amendment by applicant (claims and/or description)
17.03.2017Despatch of a communication from the examining division (Time limit: M06)
25.09.2017Reply to a communication from the examining division
14.03.2018Despatch of a communication from the examining division (Time limit: M06)
30.10.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
09.01.2019Reply to a communication from the examining division
20.08.2019Despatch of a communication from the examining division (Time limit: M02)
30.10.2019Reply to a communication from the examining division
16.01.2020Communication of intention to grant the patent
01.05.2020Fee for grant paid
01.05.2020Fee for publishing/printing paid
01.05.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20176195.4  / EP3750544
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.03.2017
Opposition(s)11.03.2021No opposition filed within time limit [2021/20]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
09.01.2019Request for further processing filed
09.01.2019Full payment received (date of receipt of payment)
Request granted
31.01.2019Decision despatched
Fees paidRenewal fee
19.09.2014Renewal fee patent year 03
02.11.2015Renewal fee patent year 04
08.11.2016Renewal fee patent year 05
27.12.2017Renewal fee patent year 06
27.11.2018Renewal fee patent year 07
27.11.2019Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
30.11.201706   M06   Fee paid on   27.12.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.11.2012
AL10.06.2020
AT10.06.2020
CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
MK10.06.2020
MT10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
TR10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
BE30.11.2020
CH30.11.2020
IE30.11.2020
LI30.11.2020
LU30.11.2020
[2022/33]
Former [2022/32]HU30.11.2012
AL10.06.2020
AT10.06.2020
CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
MK10.06.2020
MT10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
TR10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
CH30.11.2020
IE30.11.2020
LI30.11.2020
LU30.11.2020
Former [2022/27]HU30.11.2012
AL10.06.2020
AT10.06.2020
CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
MT10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
TR10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
CH30.11.2020
IE30.11.2020
LI30.11.2020
LU30.11.2020
Former [2022/26]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
TR10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
CH30.11.2020
IE30.11.2020
LI30.11.2020
LU30.11.2020
Former [2021/46]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
CH30.11.2020
IE30.11.2020
LI30.11.2020
LU30.11.2020
Former [2021/37]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
CH30.11.2020
LI30.11.2020
LU30.11.2020
Former [2021/33]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
LU30.11.2020
Former [2021/31]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/24]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/20]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/10]AL10.06.2020
AT10.06.2020
CZ10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
NL10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/09]AL10.06.2020
AT10.06.2020
CZ10.06.2020
EE10.06.2020
ES10.06.2020
FI10.06.2020
HR10.06.2020
IT10.06.2020
LT10.06.2020
LV10.06.2020
NL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
PT12.10.2020
Former [2021/04]AL10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
NL10.06.2020
RS10.06.2020
SE10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
Former [2021/01]FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
RS10.06.2020
SE10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
Former [2020/51]FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
RS10.06.2020
SE10.06.2020
NO10.09.2020
GR11.09.2020
Former [2020/50]FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
SE10.06.2020
NO10.09.2020
GR11.09.2020
Former [2020/48]FI10.06.2020
LT10.06.2020
SE10.06.2020
NO10.09.2020
Former [2020/47]LT10.06.2020
NO10.09.2020
Documents cited:Search[A]WO2008079521  (VERTEX PHARMA [US], et al) [A] 1-10,13-17 * abstract * * paragraph [0001] * * paragraph [0004] - paragraph [0006] * * paragraph [0050] * * paragraph [0052] ** claims 1-23 *;
 [A]WO2008109517  (UNIV SOUTH FLORIDA [US], et al) [A] 1-10,13-17 * abstract * * page 4, line 8 - line 16 * * claims 1-19 *;
 [XI]WO2008157208  (INCYTE CORP [US], et al) [X] 1-3,7-9,16,17 * abstract * * page 1, line 8 - line 12 * * page 2, line 17 - page 3, line 17 * * page 5, line 8 - line 15 * * page 5, line 25 - line 28 * * page 7, line 30 - line 34 * * claims 1-12,20 * [I] 1-10,13-17;
 [XI]WO2008157207  (INCYTE CORP [US], et al) [X] 1-3,7-9,16,17 * abstract * * page 1, line 8 - line 12 * * page 2, line 16 - page 3, line 18 * * table 1 * * page 9, line 30 - line 33 * * page 10, line 13 - line 16 * * page 12, line 20 - line 26 * * claims 1-7,15,16 * [I] 1-10,13-17
International search[Y]WO2006096270  (VERTEX PHARMA [US], et al);
 [Y]WO2009045975  (RFS PHARMA LLC [US], et al);
 [Y]US7593820  (WILKS ANDREW FREDERICK [AU], et al);
 [X]WO2011109217  (IMMUNODIAGNOSTICS INC [US], et al)
Examination   - YOSHIAKI TAKAHASHI ET AL, "In Vivo Administration of a JAK3 Inhibitor to Chronically SIV Infected Rhesus Macaques Leads to NK Cell Depletion Associated with Transient Modest Increase in Viral Loads", PLOS ONE, (20130701), vol. 8, no. 7, doi:10.1371/journal.pone.0070992, page e70992, XP055597203

DOI:   http://dx.doi.org/10.1371/journal.pone.0070992
by applicantUS4522811
 US4530840
 US4622219
 US4725442
 US4767628
 WO8902733
 US4891225
 EP0350287
 WO9000555
 US4906474
 US4938763
 US4957744
 EP0109942
 US5057540
 WO9116920
 WO9118914
 WO9119721
 US5149794
 WO9300910
 US5194654
 US5223263
 US5256641
 WO9426273
 EP0362279
 US5411947
 US5419917
 US5432272
 US5458888
 US5463092
 US5472708
 US5494682
 US5505962
 US5508040
 WO9611711
 WO9615132
 US5533995
 US5540938
 US5543389
 US5543390
 US5543391
 US5545409
 US5554728
 US5558879
 US5567441
 WO9633739
 US5578325
 US5580580
 WO9705185
 US5616345
 US5626863
 US5629009
 US5637320
 US5641745
 US5641515
 US5718921
 US5728402
 US5736159
 US5749847
 WO9910008
 US5994321
 US2003157135
 US6610847
 US2003162775
 US6627754
 US6635762
 US6696567
 US2004121316
 US2004157804
 US2004167124
 US2004186157
 US2004224917
 US2004224916
 US2005059637
 US6890929
 US2005137199
 US2005197320
 US2005209197
 US2005239753
 US6962993
 US2005282839
 US2006128780
 US2006128692
 US2006172973
 US7091208
 WO2006096270
 US7125855
 US2006276466
 US2006293334
 WO2007019098
 US2007049754
 US7192963
 US2007072831
 WO2007050668
 US2007111985
 US2007112190
 US2007111984
 US2007123524
 US2007129379
 US2007161639
 US2007179196
 US2007249031
 US2007259869
 US2007259823
 US2007281917
 US2007281911
 US2008004265
 US2008009490
 US2008015187
 US2008021013
 US2008020010
 US2008032963
 US2008039457
 US2008039487
 US2008058315
 US2008070920
 US2008125594
 US2008139579
 US2008153783
 US2008161350
 US2008167287
 US7399787
 US2008188500
 US2008207618
 US2008221154
 WO2008109517
 US2008261973
 US2008287394
 US2008306051
 US2008312259
 US2008312258
 WO2008157208
 WO2008157207
 US2009018162
 US2009029939
 US2009035324
 US2009036408
 US2009047252
 US2009093482
 US2009093467
 US2009098137
 US2009099366
 US2009143314
 US2009175820
 US2009181938
 US2009181959
 US2009181902
 US2009186869
 US7569569
 US2009197869
 US2009202470
 US2009215766
 US2009221571
 US2009227621
 US2009233903
 US2009233964
 US7598257
 US7601727
 US2009257978
 US2009286778
 US2009291952
 US2009291921
 US2009318405
 US2010009978
 US2010022522
 US7687507
 US2010081657
 US2010081645
 US2010160287
 US2010190804
 USRE41783E
 US7803805
 US2010280026
 US7842699
 US2010311743
 US2010310675
 US2010311693
 US2011020469
 US2011082159
 US2011086835
 US2011086810
 US2011092499
 US2011118255
 US2011136781
 US2011207754
 WO2011109217
 US2011224157
 US2011223210
 US2011245256
 US2011251215
    - VELOTTA et al., "A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection", Transplantation, (20090315), vol. 87, no. 5, pages 653 - 9
    - BOSQUEPLANELLES, "Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells", Blood, (20090000), vol. 113, pages 58 - 65
    - JORDAN et al., "HIV reproducibly establishes a latent infection after acute infection of T cells in vitro", The EMBO Journal, (20030000), vol. 22, no. 8, doi:10.1093/emboj/cdg188, pages 1868 - 1877, XP002968599

DOI:   http://dx.doi.org/10.1093/emboj/cdg188
    - "Surface modification of polymeric biomaterials for reduced thrombogenicity", Polym. Mater. Sci. Eng., (19910000), vol. 62, page 731 735
    - HO, D. H. W., "Distribution of Kinase and deaminase of 1Ø-D-arabinofuranosylcytosine in tissues of man and muse", Cancer Res., (19730000), vol. 33, page 2816 2820
    - PAN-ZHOU X-RCUI LZHOU X-JSOMMADOSSI J-PDARLEY-USMER VM, "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells", Antimicrob. Agents Chemother., (20000000), vol. 44, pages 398,408 - 503
    - Biochem., (19720000), vol. 11, pages 942 - 944
    - "Acyclic purine nucleoside phosphonates as retrovirus inhibitors", BALZARINI, J.DE CLERCQ, E., Antiviral chemotherapy, John Wiley & Sons, Inc., (19950000), pages 41 - 45
    - NAIR et al., J Med Chem., (20060126), vol. 49, no. 2, pages 445 - 447
    - PAIS et al., J Med Chem., (20020718), vol. 45, no. 15, pages 3184 - 94
    - DIVITA et al., Antiviral Research, (20060900), vol. 71, no. 2-3, pages 260 - 267
    - VATAKIS, Journal of Virology, (20090400), vol. 83, no. 7, pages 3374 - 3378
    - ZHU et al., "Irreversible Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Dicaffeoylquinic Acids", Journal of Virology, (19990400), vol. 73, no. 4, pages 3309 - 3316, XP000916737
    - MAZUMDER, A.N. NEAMATIJ. P. SOMMADOSSIG. GOSSELINR. F. SCHINAZIJ. L. IMBACHY. POMMIER, "Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase", Mol. Pharmacol., (19960000), vol. 49, pages 621 - 628, XP002920204
    - KULKARNI et al., "Polylactic acid for surgical implants", Arch. Surg., (19660000), vol. 93, page 839
    - R. JONESN. BISCHOFBERGER, Antiviral Research, (19950000), vol. 27, page 1 17
    - KUCERA, L. S.N. IYERE. LEAKEA. RABENMODEST E. K.D. L. W.C. PIANTADOSI, "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation", AIDS Res. Hum. Retroviruses, (19900000), vol. 6, page 491 501
    - PIANTADOSI, C.J. MARASCO C. J.S. L. MORRIS-NATSCHKEK. L. MEYERF. GUMUSJ. R. SURLESK. S. ISHAQL. S. KUCERAN. IYERC. A. WALLEN, "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity", J. Med. Chem., (19910000), vol. 34, doi:10.1021/jm00108a025, pages 1408 - 1414, XP002201556

DOI:   http://dx.doi.org/10.1021/jm00108a025
    - HOSTELLER, K. Y.D. D. RICHRNAND. A. CARSONL. M. STUHMILLERG. M. T. VAN WIJKH. VAN DEN BOSCH, "Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine", Antimicrob. Agents Chemother, (19920000), vol. 36, pages 2025 - 2029
    - HOSTETLER, K. Y.L. M. STUHMILLERH. B. LENTINGH. VAN DEN BOSCHD. D. RICHMAN, "Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides", J. Biol. Chem., (19900000), vol. 265, page 61127
    - "Isopolar phosphorous-modified nucleotide analogues", HOLY, A., Advances in Antiviral Drug Design, JAI Press, (19930000), vol. I, page 179 231
    - HONG, C. I.NECHAEV, A.WEST, C. R., "Synthesis and antitumor activity of 1Ø-D-arabino-furanosylcytosine conjugates of cortisol and cortisone", Biochem. Biophys. Rs. Commun., (19790000), vol. 88, page 1223 1229
    - HONG, C. I.NECHAEV, A.KIRISITS, A. J.BUCHHEIT, D. J.WEST, C. R., "Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(p-D-arabinofuranosyl)cytosine conjugates of corticosteroids and selected lipophilic alcohols", J. Med. Chem., (19800000), vol. 28, page 171 177
    - HOSTELLER, K. Y.STUHMILLER, L. M.LENTING, H. B. M.VAN DEN BOSCH, H.RICHMAN, J Biol. Chem., vol. 265, page 6112 6117
    - HOSTELLER, K. Y.CARSON, D. A.RICHMAN, D. D., "Phosphatidylazidothymidine: mechanism of antiretroviral action in CEM cells", J. Biol Chem., (19910000), vol. 266, page 11714 11717
    - HOSTELLER, K. Y.KORBA, B.SRIDHAR, C.GARDENER, M., "Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice", Antiviral Res., (19940000), vol. 24, page 59 67
    - HOSTELLER, K. Y.RICHMAN, D. D.SRIDHAR. C. N.FEIGNER, P. L.FEIGNER, J.RICCI, J.GARDENER, M. F.SELLESETH, D. W.ELLIS, M. N., "Phosphatidylazidothymidine and phosphatidyl-ddC: Assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in rauscher leukemia virus-infected mice", Antimicrobial Agents Chemother, (19940000), vol. 38, page 2792 2797
    - HUNSTON, R. N.JONES, A. A.MCGUIGAN, C.WALKER, R. T.BALZARINI, J.DECLERCQ, E., "Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine", J. Med. Chem., (19840000), vol. 27, pages 440 - 444
    - JI, Y. H.MOOG, C.SCHMITT, G.BISCHOFF, P.LUU, B., "Monophosphoric acid esters of 7-0-hydroxycholesterol and of pyrimidine nucleoside as potential antitumor agents: synthesis and preliminary evaluation of antitumor activity", J. Med. Chem., (19900000), vol. 33, page 2264 2270
    - JONES, A. S.MCGUIGAN, C.WALKER, R. T.BALZARINI, J.DECLERCQ, E., "Synthesis, properties, and biological activity of some nucleoside cyclic phosphoramidates", J. Chem. Soc. Perkin Trans., (19840000), vol. I, page 1471 1474
    - JUODKA, B. A.SMART, J., "Synthesis of diribonucleoside phosph (P.fwdarw.N) amino acid derivatives", Coll. Czech. Chem. Comm., (19740000), vol. 39, page 363 968
    - KATAOKA, S.IMAI, J.YAMAJI, N.KATO, M.SAITO, M.KAWADA, T.IMAI, S., "Alkylated cAMP derivatives; selective synthesis and biological activities", Nucleic Acids Res. Sym. Ser., (19890000), vol. 21, page 1 2
    - KATAOKA, S., UCHIDA, "cAMP) benzyl and methyl triesters", Heterocycles, vol. 32, page 1351 1356
    - KINCHINGTON, D.HARVEY, J. J.O'CONNOR, T. J.JONES, B. C. N. M.DEVINE, K. G.TAYLOR-ROBINSON D.JEFFRIES, D. J.MCGUIGAN, C., "Comparison of antiviral effects of zidovudine phosphoramidate and phosphorodiamidate derivatives against HIV and ULV in vitro", Antiviral Chem. Chemother., (19920000), vol. 3, page 107 112
    - KODAMA, K.MOROZUMI, M.SAITHOH, K. I.KUNINAKA, H.YOSINO, H.SANEYOSHI, M., "Antitumor activity and pharmacology of I-β-D-arabinofuranosylcytosine -5'-stearylphosphate; an orally active derivative of I-β-Darabinofuranosylcytosine", Jpn. J. Cancer Res., (19890000), vol. 80, page 679 685
    - KORTY, M.ENGELS, J., "The effects of adenosine- and guanosine 3',5' phosphoric and acid benzyl esters on guinea-pig ventricular myocardium", Naunyn-Schmiedeberg's Arch. Pharmacol., (19790000), vol. 310, page 103 111
    - KUMAR, A.GOE, P. L.JONES, A. S.WALKER, R. T.BALZARINI, J.DECLERCQ, E., "Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives", J. Med. Chem, (19900000), vol. 33, page 2368 2375
    - LEBEC, C.HUYNH-DINH, T., "Synthesis of lipophilic phosphate triester derivatives of 5-fluorouridine an arabinocytidine as anticancer prodrugs", Tetrahedron Lett., (19910000), vol. 32, page 6553 6556
    - LICHTENSTEIN, J.BARNER, H. D.COHEN, S. S., "The metabolism of exogenously supplied nucleotides by Escherichia coli.", J. Biol. Chem., (19600000), vol. 235, page 457 465
    - LUCTHY, J.VON DAENIKEN, A.FRIEDERICH, J.MANTHEY, B.ZWEIFEL, J.SCHLATTER, C.BENN, M. H., "Synthesis and toxicological properties of three naturally occurring cyanoepithioalkanes", Mitt. Geg. Lebensmittelunters. Hyg., (19810000), vol. 72, page 131 133
    - MCGIGAN, C.TOLLERFIELD, S. M.RILEY, P. A., "Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug Ara", Nucleic Acids Res., (19890000), vol. 17, page 6065 6075
    - MCGUIGAN, C.DEVINE, K. G.O'CONNOR, T. J.GALPIN, S. A.JEFFRIES, D. J.KINCHINGTON, D., "Synthesis and evaluation of some novel phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT) as anti-HIV compounds", Antiviral Chem. Chemother., (19900000), vol. 1, page 107 113
    - MCGUIGAN, C.O'CONNOR, T. J.NICHOLLS, S. R.NICKSON, C.KINCHINGTON, D., "Synthesis and anti-HIV activity of some novel substituted dialkyl phosphate derivatives of AZT and ddCyd", Antiviral Chem. Chemother., (19900000), vol. 1, page 355 360
    - MCGUIGAN, C.NICHOLLS, S. R.O'CONNOR, T. J.KINCHINGTON, D., "Synthesis of some novel dialkyl phosphate derivative of 3'-modified nucleosides as potential anti-AIDS drugs", Antiviral Chem. Chemother., (19900000), vol. 1, page 25 33
    - MCGUIGAN, C.DEVIN, K. G.O'CONNOR, T. J.KINCHINGTON, D., "Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3'-azido-3'-deoxythylmidine (AZT); potent activity of the trichloroethyl methoxyalaninyl compound", Antiviral Res., (19910000), vol. 15, page 255 263
    - MCGUIGAN, C.PATHIRANA, R. N.BALZARINI, J.DECLERCQ, E., "Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT", J. Med. Chem., (19930000), vol. 36, page 1048 1052
    - Antiviral Chem. Chemother., vol. 5, page 271 277
    - MEYER, R. B., JR.SHUMAN, D. A.ROBINS, R. K., "Synthesis of purine nucleoside 3',5'-cyclic phosphoramidates", Tetrahedron Lett., (19730000), page 269 272
    - NAGYVARY, J.GOHIL, R. N.KIRCHNER, C. R.STEVENS, J. D., "Studies on neutral esters of cyclic AMP", Biochem. Biophys. Res. Commun., (19730000), vol. 55, page 1072 1077
    - NAMANE, A.GOUYETTE, C.FILLION, M. P.FILLION, G.HUYNH-DINH, T., "Improved brain delivery of AZT using a glycosyl phosphotriester prodrug", J. Med. Chem., (19920000), vol. 35, pages 3039 - 3044
    - NARGEOT, J.NERBONNE, J. M.ENGELS, J.LESER, H. A., Natl. Acad. Sci. U.S.A., (19830000), vol. 80, page 2395 2399
    - NELSON, K. A.BENTRUDE, W. G.STSER, W. N.HUTCHINSON, J. P., "The question of chair-twist equilibria for the phosphate rings of nucleoside cyclic 3',5'-monophosphates. HNMR and x-ray crystallographic study of the diastereomers of thymidine phenyl cyclic 3',5'-monophosphate", J. Am. Chem. Soc., (19870000), vol. 109, page 4058 4064
    - NERBONNE, J. M.RICHARD, S.NARGEOT, J.LESTER, H. A., "New photoactivatable cyclic nucleotides produce intracellular jumps in cyclic AMP and cyclic GMP concentrations", Nature, (19840000), vol. 301, page 74 76
    - NEUMANN, J. M.HERV_, M.DEBOUZY, J. C.GUERRA, F. I.GOUYETTE, C.DUPRAZ, B.HUYNY-DINH, T., "Synthesis and transmembrane transport studies by NMR of a glucosyl phospholipid of thymidine", J. Am. Chem. Soc., (19890000), vol. 111, page 4270 4277
    - OHNO, R.TATSUMI, N.HIRANO, M.IMAI, K.MIZOGUCHI, H.NAKAMURA, T.KOSAKA, M.TAKATUSKI, K.YAMAYA, T.TOYAMA K., "Treatment of myelodysplastic syndromes with orally administered I-β-D-arabinouranosylcytosine -5' stearylphosphate", Oncology, (19910000), vol. 48, page 451 455
    - PALOMINO, E.KESSLE, D.HORWITZ, J. P., "A dihydropyridine carrier system for sustained delivery of 2',3' dideoxynucleosides to the brain", J. Med. Chem., (19890000), vol. 32, page 22 625
    - PERKINS, R. M.BARNEY, S.WITTROCK, R.CLARK, P. H.LEVIN, R.LAMBERT, D. M.PETTEWAY, S. R.SERAFINOWSKA, H. T.BAILEY, S. M.JACKSON, S., "Activity of BRL47923 and its oral prodrug, SB203657A against a rauscher murine leukemia virus infection in mice", Antiviral Res., (19930000), vol. 20, no. 1, page 84
    - PIANTADOSI, C.MARASCO, C. J., JR.NORRIS-NATSCHKE, S. L.MEYER, K. L.GUMUS, F.SURLES, J. R.LSHAQ, K. S.KUCERA, L. S.IYER, N.WALLEN, C. A., "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity", J. Med. Chem., (19910000), vol. 34, page 1408 1414
    - POMPON, A.LEFEBVRE, I.IMBACH, J. L.KAHN, S.FARQUHAR, D., "Decomposition pathways of the mono- and bis(pivaloyloxymethyl) esters of azidothymidine-5'-monophosphate in cell extract and in tissue culture medium; an application of the ''on-line ISRP-cleaning HPLC technique", Antiviral Chem Chemother., (19940000), vol. 5, page 91 98
    - POSTEMARK, T., "Cyclic AMP and cyclic GMP", Annu. Rev. Pharmacol., (19740000), vol. 14, page 23 33
    - PRISBE, E. J.MARTIN, J. C. M.MCGHEE, D. P. C.BARKER, M. F.SMEE, D. F.DUKE, A. E.MATTHEWS, T. R.VERHEYDEN, J. P. J., "Synthesis and antiherpes virus activity of phosphate an phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine", J. Med. Chem., (19860000), vol. 29, page 671 675
    - PUCCH, F.GOSSELIN, G.LEFEBVRE, I.POMPON, A.AUBERTIN, A. M. DIMIMBACH, J. L., "Intracellular delivery of nucleoside monophosphate through a reductase-mediated activation process", Antiviral Res., (19930000), vol. 22, page 155 174
    - PUGAEVA, V. P.KLOCHKEVA, S. I.MASHBITS, F. D.EIZENGART, R. S., "Toxicological assessment and health standard ratings for ethylene sulfide in the industrial atmosphere", Gig. Trf. Prof. Zabol., (19690000), vol. 14, page 47 48
    - ROBINS, R. K., "The potential of nucleotide analogs as inhibitors of Retro viruses and tumors", Pharm. Res., (19840000), vol. 11, page 18
    - ROSOWSKY, A.KIM. S. H.ROSSJ. WICK, M. M., "Lipophilic 5'-(alkylphosphate) esters of 1-P-D-arabinofiiranosylcytosine and its N4-acyl and 2.2'-anhydro-3'-O-acyl derivatives as potential prodrugs", J. Med. Chem., (19820000), vol. 25, page 171 178
    - ROSS, W., "Increased sensitivity of the walker turnout towards aromatic nitrogen mustards carrying basic side chains following glucose pretreatment", Biochem. Pharm., (19610000), vol. 8, page 235 240
    - RYU, E. K.ROSS, R. J.MATSUSHITA, T.MACCOSS, M.HONG, C. I.WEST, C. R., "Phospholipid-nucleoside conjugates. 3. Synthesis and preliminary biological evaluation of 1-P-D-arabinofuranosylcytosine 5'diphosphate [-], 2-diacylglycerols", J. Med. Chem., (19820000), vol. 25, page 1322 1329
    - SAFFHILL, R.HUME, W. J., "The degradation of 5-iododeoxyuridine and 5-bromoethoxyuridine by serum from different sources and its consequences for the use of these compounds for incorporation into DNA", Chem. Biol. Interact., (19860000), vol. 57, page 347 355
    - SANEYOSHI, M.MOROZUMI, M.KODAMA, K.MACHIDA, J.KUNINAKA, A.YOSHINO, H., "Synthetic nucleosides and nucleotides. XVI. Synthesis and biological evaluations of a series of I-β-D-arabinofuranosylcytosine 5'-alky or arylphosphates", Chem Pharm. Bull., (19800000), vol. 28, page 2915 2923
    - SASTRY, J. K.NEHETE, P. N.KHAN, S.NOWAK, B. J.PLUNKETT, W.ARLINGHAUS, R. B.FARQUHAR, D., "Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection", Mol. Pharmacol., (19920000), vol. 41, page 441 445
    - SHUTO, S.UEDA, S.IMAMURA, S.FUKUKAWA, K.MATSUDA, A.UEDA, T., "A facile one-step synthesis of 5' phosphatidiylnucleosides by an enzymatic two-phase reaction", Tetrahedron Lett., (19870000), vol. 28, page 199 202
    - SHUTO, S.ITOH, H.UEDA, S.IMAMURA, S.KUKUKAWA, K.TSUJINO, M.MATSUDA, A.UEDA, T., Pharm. Bull., (19880000), vol. 36, page 209 217
    - KRIEG A et al., Nature, (19950000), vol. 374, page 546
    - CHU R et al., J. Exp. Med., (19970000), vol. 186, page 1623
    - ZAJONCKRENENBERG, Current Opinion in Structural Biology, (20070000), vol. 17, pages 521 - 529
    - KLINMAN, Nature Reviews, (20040000), vol. 4, page 249
    - LACAILLE-DUBOIS, MWAGNER H., "A review of the biological and pharmacological activities of saponins", Phytomedicine, (19960000), vol. 2, pages 363 - 386, XP000993545
    - KENSIL, C. R., "Saponins as vaccine adjuvants", Crit Rev Ther Drug Carrier Syst, (19960000), vol. 12, no. 1-2, pages 1 - 55
    - KENSIL et al., J. Immunology, (19910000), vol. 146, pages 431 - 437
    - BOMFORD et al., Vaccine, (19920000), vol. 10, no. 9, pages 572 - 577
    - OKAMURA H. et al., Adv. Immunol., (19980000), vol. 70, pages 281 - 312
    - DANIELS, M. D. et al., Science, (19920000), vol. 258, page 1938
    - DESROSIERS, R. C. et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, page 6353
    - GIBBS, J. S. et al., AIDS Res. and Human Retroviruses, (19940000), vol. 10, page 343
    - IGARASHI, T. et al., J. Gen. Virol., (19970000), vol. 78, page 985
    - KESTLER III, H. W. et al., Cell, (19910000), vol. 65, page 651
    - COONEY E L et al., Proc Natl Acad Sci USA, (19930000), vol. 90, pages 1882 - 86
    - MCELRATH M J et al., J Infect Dis., (19940000), vol. 169, pages 41 - 47
    - GRAHAM B S et al., J Infect Dis, (19920000), vol. 166, pages 244 - 52
    - GRAHAM B S et al., J Infect Dis, (19930000), vol. 167, pages 533 - 37
    - JAMES et al., AIDS Res. Human Retrovirus, (19940000), vol. 10, pages 343 - 350
    - SCHINAZI R.F.SOMMADOSSI J.-P.SAALMANN V.CANNON D.L.XIE M.-Y.HART G.C.SMITH G.A.HAHN E.F., Antimicrob. Agents Chemother., (19900000), vol. 34, pages 1061 - 67
    - CHOU T.-C.TALALAY P., Adv. Enzyme Regul., (19840000), vol. 22, pages 27 - 55
    - BELEN'KII M.S.SCHINAZI R.F., Antiviral Res., (19940000), vol. 25, pages 1 - 11
    - STUYVER LJLOSTIA SADAMS MMATHEW JSPAI BSGRIER JTHARNISH PMCHOI YCHONG YCHOO H, "Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogs", Antimicrob. Agents Chemother., (20020000), vol. 46, pages 3854 - 60
    - "GenBank", Database accession no. E01094
    - JOHNSON MRK WANGJB SMITHMJ HESLINRB DIASIO, "Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction", Anal. Biochem., (20000000), vol. 278, pages 175 - 184
    - CUI LSCHINAZI RFGOSSELIN GIMBACH JLCHU CKRANDO RFREVANKAR GRSOMMADOSSI JP, "Effect of enantiomeric and racemic nucleoside analogs on mitochondrial functions in HepG2 cells", Biochem. Pharmacol., (19960000), vol. 52, doi:10.1016/S0006-2952(96)00562-X, pages 1577 - 1584, XP002968516

DOI:   http://dx.doi.org/10.1016/S0006-2952(96)00562-X
    - LEWIS WLEVINE ESGRINIUVIENE BTANKERSLEY KOCOLACINO JMSOMMADOSSI JPWATANABE KAPERRINO FW, "Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts", Proc Natl Acad Sci USA., (19960000), vol. 93, doi:10.1073/pnas.93.8.3592, pages 3592 - 7, XP002115121

DOI:   http://dx.doi.org/10.1073/pnas.93.8.3592
    - RAY ASHERNANDEZ-SANTIAGO BIMATHEW JSMURAKAMI EBOZEMAN CXIE MYDUTSCHMAN GEGULLEN EYANG ZHURWITZ S, "Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine", Antimicrob. Agents Chemother., (20050000), vol. 49, pages 1994 - 2001
    - SOMMADOSSI JPCARLISLE R, "Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine for normal human hepatopoietic progenitor cells in vitro", Antimicrob. Agents Chemother., (19870000), vol. 31, pages 452 - 454
    - SOMMADOSSI, JPSCHINAZI, RFCHU, CKXIE, MY, "Comparison of Cytotoxicity of the (-) and (+) enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells", Biochem. Pharmacol., (19920000), vol. 44, doi:10.1016/0006-2952(92)90093-X, pages 1921 - 1925, XP025541685

DOI:   http://dx.doi.org/10.1016/0006-2952(92)90093-X
    - LADNER S.K.OTTO M.J.BARKER C.S.ZAIFERT K.WANG G.H.GUO J.T.SEEGER C.KING R.W., Antimicrob. Agents Chemother., (19970000), vol. 41, pages 1715 - 20
    - STUYVER L et al., "Ribonucleoside analogue that blocks replication or bovine viral diarrhea and hepatitis C viruses in culture", Antimicrob. Agents Chemother., (20030000), vol. 47, doi:10.1128/AAC.47.1.244-254.2003, pages 244 - 254, XP055169861

DOI:   http://dx.doi.org/10.1128/AAC.47.1.244-254.2003
    - REED IJMUENCH H, "A simple method or estimating fifty percent endpoints", Am. J. Hyg., (19380000), vol. 27, page 497
    - SONG, G.Y.PAUL, V.CHOO, H.MORREY, J.SIDWELL, R.W.SCHINAZI, R.F.CHU, C.K., "Enantiomeric synthesis of D- and L-cyclopentenyl nucleosides and their antiviral activity against HIV and West Nile virus", J. Med. Chem., (20010000), vol. 44, pages 3985 - 3993
    - JULANDER, J.G.FURUTA, Y.SHAFER, K.SIDWELL, R.W., "Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection", Antimicrob. Agents Chemother., (20070000), vol. 51, pages 1962 - 1966
    - LIM et al., "A scintillation proximity assay for dengue virus NS5 2'-O-methyltransferase-kinetic and inhibition analyses", Antiviral Research, (20081200), vol. 80, no. 3, doi:10.1016/j.antiviral.2008.08.005, pages 360 - 369, XP025684752

DOI:   http://dx.doi.org/10.1016/j.antiviral.2008.08.005
    - LIM et al., Antiviral Research, (20081200), vol. 80, no. 3, pages 360 - 369
    - CHANG, K. O. et al., Virology, (20060000), vol. 353, pages 463 - 473
    - STRAUB, T. M. et al., Emerg. Infect. Dis., (20070000), vol. 13, no. 3, pages 396 - 403
    - BAGINSKI, S. G.PEVEAR, D. C.SEIPEL, M.SUN, S. C. C.BENETATOS, C. A.CHUNDURU, S. K.RICE, C. M.M. S. COLLETT, "Mechanism of action of a pestivirus antiviral compound", PNAS USA, (20000000), vol. 97, no. 14, pages 7981 - 7986
    - STUYVER, L. J. et al., Antimicrob. Agents Chemother., (20060000), vol. 47, pages 244 - 254
 US20090306198
 US20090217496
 US20070586627
 EP19930917054
 US20030423496
 US20030424130
 US20030424186
 US20030687374
 US20030687373
 US20040757141
 US20040757122
 US20040903288
 US20040944118
 US20050033422
 US20050040929
 US20050047229
 US20050587857
 US20050511182
 US20050587601
 US20050592222
 US20050591914
 US20050587682
 US20050579772
 US20050629153
 US20050658419
 US20050190225
 US20050585504
 US20060435671
 US20060500387
 US20060505149
 US20060992531
 US20060590637
 US20060595429
 US20060599580
 US20060561039
 US20060641508
 US20060644811
 US20060097859
 US20070162975
 US20070804041
 US20070807303
 US20070754462
 US20070820444
 US20070767021
 US20070768458
 US20070827959
 US20070880854
 US20070853606
 US20080042628
 US20080043636
 US20080132145
 US20080215605
 US20080215601
 US20080147220
 US20080147041
 US20080215266
 US20080169367
 US20080195161
 US20080204174
 US20080208952
 US20080274107
 US20080340419
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.